Latest news with #ANR
Business Wire
27-05-2025
- Health
- Business Wire
Preclinical Data on Circle Pharma's CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C., May 25-28, 2025. The data, which explore the therapeutic potential of CID-078 in neuroblastoma (NB), were presented in a poster entitled: 'Cyclin A/B-RxL Inhibition as a Novel Therapeutic Strategy in Neuroblastoma' Dylan M.M. Jongerius et al. Poster #P010 The poster highlights the work of researchers from the Princess Máxima Center for Pediatric Oncology (Utrecht, the Netherlands), the Hopp Children's Cancer Center Heidelberg (KiTZ) (Heidelberg, Germany), and Circle Pharma, demonstrating the potent anti-tumor activity of CID-078 in preclinical neuroblastoma (NB) models. CID-078 is a first-in-class oral macrocycle cyclin A/B RxL inhibitor that selectively disrupts RxL-mediated interactions between cyclin A2/B1 and their substrates, a novel mechanism of action that targets cell cycle dysregulation in cancer. In neuroblastoma, where CDK-RB-E2F axis deregulation and oncogenic E2F activity are common, this mechanism is particularly relevant. Key Findings Presented: Potent Single agent CID-078 activity was observed across multiple neuroblastoma cell line models. Mechanism of action studies confirmed induction of DNA damage, G2/M arrest and the activation of the spindle assembly checkpoint (SAC). Deletion of CDKN2A sensitized cells to CID-078 suggesting CDKN2A status maybe be used as a potential patient stratification strategy. 'A greater understanding of the biology of neuroblastoma, the most common extra-cranial solid tumor diagnosed in children, has shown specific genomic alterations which deregulate the cell cycle leading to E2F activation,' said Michael C. Cox, PharmD, MHSc, BCOP, SVP and head of early development of Circle Pharma. 'Circle's collaboration with these two premier pediatric oncology research institutions has shown again the potential of our macrocycle platform to develop new therapies for historically challenging targets. The exciting CDKN2A deletion biomarker data, as well as the in vitro data in a pediatric tumor with a need for better treatments support our clinical development plans for CID-078.' The full poster is available here. About CID-078, Circle Pharma's Cyclin A/B RxL Inhibitor Program CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation. In biochemical and cellular studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and Myt1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center phase 1 clinical trial (NCT06577987) is currently enrolling patients. About Circle Pharma, Inc. South San Francisco-based Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. Its lead program, CID-078, a cyclin A/B-RxL inhibitor, is in a Phase 1 clinical trial (NCT06577987) for patients with advanced solid tumors. To learn more about Circle Pharma, please visit
Yahoo
27-05-2025
- Business
- Yahoo
Preclinical Data on Circle Pharma's CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting
SOUTH SAN FRANCISCO, Calif., May 27, 2025--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C., May 25-28, 2025. The data, which explore the therapeutic potential of CID-078 in neuroblastoma (NB), were presented in a poster entitled: "Cyclin A/B-RxL Inhibition as a Novel Therapeutic Strategy in Neuroblastoma"Dylan M.M. Jongerius et #P010 The poster highlights the work of researchers from the Princess Máxima Center for Pediatric Oncology (Utrecht, the Netherlands), the Hopp Children's Cancer Center Heidelberg (KiTZ) (Heidelberg, Germany), and Circle Pharma, demonstrating the potent anti-tumor activity of CID-078 in preclinical neuroblastoma (NB) models. CID-078 is a first-in-class oral macrocycle cyclin A/B RxL inhibitor that selectively disrupts RxL-mediated interactions between cyclin A2/B1 and their substrates, a novel mechanism of action that targets cell cycle dysregulation in cancer. In neuroblastoma, where CDK-RB-E2F axis deregulation and oncogenic E2F activity are common, this mechanism is particularly relevant. Key Findings Presented: Potent Single agent CID-078 activity was observed across multiple neuroblastoma cell line models. Mechanism of action studies confirmed induction of DNA damage, G2/M arrest and the activation of the spindle assembly checkpoint (SAC). Deletion of CDKN2A sensitized cells to CID-078 suggesting CDKN2A status maybe be used as a potential patient stratification strategy. "A greater understanding of the biology of neuroblastoma, the most common extra-cranial solid tumor diagnosed in children, has shown specific genomic alterations which deregulate the cell cycle leading to E2F activation," said Michael C. Cox, PharmD, MHSc, BCOP, SVP and head of early development of Circle Pharma. "Circle's collaboration with these two premier pediatric oncology research institutions has shown again the potential of our macrocycle platform to develop new therapies for historically challenging targets. The exciting CDKN2A deletion biomarker data, as well as the in vitro data in a pediatric tumor with a need for better treatments support our clinical development plans for CID-078." The full poster is available here. About CID-078, Circle Pharma's Cyclin A/B RxL Inhibitor Program CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation. In biochemical and cellular studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and Myt1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center phase 1 clinical trial (NCT06577987) is currently enrolling patients. About Circle Pharma, Inc. South San Francisco-based Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. Its lead program, CID-078, a cyclin A/B-RxL inhibitor, is in a Phase 1 clinical trial (NCT06577987) for patients with advanced solid tumors. To learn more about Circle Pharma, please visit View source version on Contacts Media Contact:Roslyn Patterson Phone: 650.825.4099 Email: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Epoch Times
14-05-2025
- Automotive
- Epoch Times
Vermont Governor Pauses EV Rules Citing Concerns Over Insufficient Charging Infrastructure
Vermont Gov. Phil Scott signed an executive order on May 13 putting the state's electric vehicle (EV) sales requirements for passenger cars and medium- and heavy-duty trucks on hold amid concerns over the feasibility of zero-emission vehicle rules and the lack of adequate charging infrastructure. Vermont The measure aimed to accelerate the state's transition to zero-emission medium- and heavy-duty vehicles by requiring manufacturers to produce vehicles certified to increasingly more stringent emission categories. Specifically, it directed manufacturers to gradually increase deliveries of new zero-emission vehicles (ZEV) for sale in Vermont to 100 percent by 2035, starting with model year 2026 vehicles. Vermont is among a dozen states—including New York, Maryland, and Massachusetts—that have adopted California's zero-emission vehicle rules or similar regulations. Despite agreeing to the new standards, Scott said on Tuesday that it was clear the state lacks sufficient charging infrastructure and technological advances in heavy-duty vehicles to be able to meet its current EV sales goals. Related Stories 5/13/2025 4/30/2025 The Republican signed an His order instructs the Vermont Department of Environmental Conservation to use its enforcement discretion to ease compliance with the plan, including by not taking action against manufacturers that do not meet their sales obligations and targets, and declining to pursue penalties against those with ZEV delivery shortfalls. According to the order, such actions will not be taken against manufacturers provided they do not impose ZEV sales ratios on dealerships and continue to supply internal combustion engine cars to dealerships seeking those vehicles. Scott's order will remain in full force until Dec. 31, 2026, or until the governor, in consultation with the Secretary of the ANR, determines whether to amend or rescind it. 'I continue to believe we should be incentivizing Vermonters to transition to cleaner energy options like electric vehicles. However, we have to be realistic about a pace that's achievable,' Scott said in a 'We have much more work to do, in order make it more convenient, faster, and more affordable to buy, maintain and charge EV's. When we do, it's more likely everyday Vermonters will make the switch.' Scott 'Committed to Addressing Climate Change' Though the ZEV rule has been put on hold, Scott's office said he remains 'committed to addressing climate change,' including advocating for more charging infrastructure across the state, which it said is essential in helping make EVs viable and reducing transportation emissions. It added that mandates are 'not going to be the total answer' when it comes to transitioning to a low-carbon future. 'Using common sense and incentivizing technological advancements is necessary to overall success and this compliance flexibility is intended to reflect this reality,' his office said. Scott's announcement was welcomed by Jack Castellaneta, president of the Vermont Vehicle and Automotive Distributors Association (VADA), who 'We need to be realistic about what's achievable and focus on building more practical solutions for our transportation sector,' Castellaneta said in a statement. Maryland Gov. Wes Moore last month issued a similar Moore's order cited concerns among manufacturers that the ZEV requirements would be too difficult to meet in the state, as well as 'indications' that the policies of the Trump administration, including its tariff plans, would 'greatly impact' compliance. In May, the House of Representatives also voted to ban California's plans to require an increasing number of zero-emission heavy-duty trucks, as well as its 2035 EV plan, a move that would repeal the legal approval for the rules granted by the Environmental Protection Agency under former President Joe Biden. California contends Congress cannot reverse the Biden administration's decision under fast-track rules. The Senate has yet to take up the measures.
Time of India
11-05-2025
- Automotive
- Time of India
Adani Group deploys India's 1st hydrogen-powered truck for mining logistics
Adani group has deployed India's first hydrogen-powered truck for mining logistics in Chhattisgarh, which can carry 40 tonnes of cargo over a 200-kilometre range, the conglomerate said Saturday. Adani Enterprises , the flagship company of the group, flagged off hydrogen fuel cell trucks as it looks to promote cleaner transportation. "These hydrogen-powered trucks will gradually replace diesel vehicles used in the company's logistics operations," the firm said in a statement. "In collaboration with an Indian and international energy technology firm and a major auto manufacturer, Adani is developing hydrogen fuel cell battery-operated trucks for cargo transport. Each truck, equipped with smart technology and three hydrogen tanks, can carry up to 40 tonnes of cargo over a 200-km range." Chhattisgarh Chief Minister Vishnu Deo Sai flagged off the first truck in Raipur. It will be used to transport coal from the Gare Pelma III Block to the state's power plant. "The launch of India's first hydrogen-powered truck in Chhattisgarh reflects the state's commitment to sustainability. Such initiatives will significantly reduce our carbon footprint and set a new standard for industry. Chhattisgarh is not only at the forefront in meeting the country's electricity demands but also leads by example in adopting sustainable practices," Sai said. The state-owned Chhattisgarh State Power Generation Company Limited has appointed Adani Enterprises as the mine developer and operator for the Gare Pelma III block through a competitive bidding process. "The initiative for hydrogen-powered trucks is a significant step towards Adani Group's commitment to decarbonisation and responsible mining. We are creating model mines with minimal environmental impact by incorporating autonomous dozer push technologies, solar power, digital initiatives, and tree transplanters to relocate trees. "We aim to ensure affordable and reliable electricity for all while pioneering new standards in sustainable mining practices," said Vinay Prakash, CEO - Natural Resources and Director, Adani Enterprises. The project is a joint effort between Adani Natural Resources (ANR) and Adani New Industries Limited (ANIL). Both entities are part of Adani Enterprises. ANR will source hydrogen cells from ANIL, which is also involved in green hydrogen , wind turbines, solar modules, and battery manufacturing. Hydrogen, the most abundant element, produces no harmful emissions. Hydrogen fuel cell vehicles match diesel trucks in range and load capacity but emit only water vapour and warm air with minimal noise. Since mining mainly uses diesel-powered machinery, switching to cleaner fuels will reduce emissions and noise. It will also help lower India's oil imports and carbon footprint. Adani Natural Resources is the first in Asia to deploy Dozer Push Semi-Autonomous Technology, boosting safety and sustainability, the statement said. ANR produces and processes coal, minerals, and metals for industries and end users. It has a diversified business portfolio consisting of integrated resources management, iron ore, copper, aluminium, minerals, bunkering, liquified petroleum gas and rock phosphate.
Time of India
11-05-2025
- Automotive
- Time of India
Adani Group deploys India's 1st hydrogen-powered truck for mining logistics
Adani group has deployed India's first hydrogen-powered truck for mining logistics in Chhattisgarh, which can carry 40 tonnes of cargo over a 200-kilometre range, the conglomerate said Saturday. Adani Enterprises , the flagship company of the group, flagged off hydrogen fuel cell trucks as it looks to promote cleaner transportation. "These hydrogen-powered trucks will gradually replace diesel vehicles used in the company's logistics operations," the firm said in a statement. "In collaboration with an Indian and international energy technology firm and a major auto manufacturer, Adani is developing hydrogen fuel cell battery-operated trucks for cargo transport. Each truck, equipped with smart technology and three hydrogen tanks, can carry up to 40 tonnes of cargo over a 200-km range." Chhattisgarh Chief Minister Vishnu Deo Sai flagged off the first truck in Raipur. It will be used to transport coal from the Gare Pelma III Block to the state's power plant. "The launch of India's first hydrogen-powered truck in Chhattisgarh reflects the state's commitment to sustainability. Such initiatives will significantly reduce our carbon footprint and set a new standard for industry. Chhattisgarh is not only at the forefront in meeting the country's electricity demands but also leads by example in adopting sustainable practices," Sai said. The state-owned Chhattisgarh State Power Generation Company Limited has appointed Adani Enterprises as the mine developer and operator for the Gare Pelma III block through a competitive bidding process. "The initiative for hydrogen-powered trucks is a significant step towards Adani Group's commitment to decarbonisation and responsible mining. We are creating model mines with minimal environmental impact by incorporating autonomous dozer push technologies, solar power, digital initiatives, and tree transplanters to relocate trees. "We aim to ensure affordable and reliable electricity for all while pioneering new standards in sustainable mining practices," said Vinay Prakash, CEO - Natural Resources and Director, Adani Enterprises. The project is a joint effort between Adani Natural Resources (ANR) and Adani New Industries Limited (ANIL). Both entities are part of Adani Enterprises. ANR will source hydrogen cells from ANIL, which is also involved in green hydrogen , wind turbines, solar modules, and battery manufacturing. Hydrogen, the most abundant element, produces no harmful emissions. Hydrogen fuel cell vehicles match diesel trucks in range and load capacity but emit only water vapour and warm air with minimal noise. Since mining mainly uses diesel-powered machinery, switching to cleaner fuels will reduce emissions and noise. It will also help lower India's oil imports and carbon footprint. Adani Natural Resources is the first in Asia to deploy Dozer Push Semi-Autonomous Technology, boosting safety and sustainability, the statement said. ANR produces and processes coal, minerals, and metals for industries and end users. It has a diversified business portfolio consisting of integrated resources management, iron ore, copper, aluminium, minerals, bunkering, liquified petroleum gas and rock phosphate.
